2013
Impact of Scheduled Angiographic Follow‐Up in Patients Treated With Primary Percutaneous Coronary Intervention for ST‐Segment Elevation Myocardial Infarction
MINDRESCU C, BRENER S, GUERCHICOFF A, FAHY M, PARISE H, MEHRAN R, STONE G. Impact of Scheduled Angiographic Follow‐Up in Patients Treated With Primary Percutaneous Coronary Intervention for ST‐Segment Elevation Myocardial Infarction. Journal Of Interventional Cardiology 2013, 26: 319-324. PMID: 23795656, DOI: 10.1111/joic.12038.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionTarget vessel revascularizationPercutaneous coronary interventionPrimary percutaneous coronary interventionElevation myocardial infarctionMyocardial infarctionCoronary interventionStent thrombosisAcute Myocardial Infarction trialMyocardial Infarction trialOutcomes of patientsRate of revascularizationAngiographic Follow-upSAF groupRate of deathHarmonizing OutcomesVessel revascularizationCerebral eventsMI ratesFollow-upPatientsRevascularizationInfarctionComposite rateDeath
2012
Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials.
Kedhi E, Stone G, Kereiakes D, Serruys P, Parise H, Fahy M, Simonton C, Sudhir K, Sood P, Smits P. Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. EuroIntervention 2012, 8: 599-606. PMID: 22995087, DOI: 10.4244/eijv8i5a92.Peer-Reviewed Original ResearchConceptsDAPT discontinuationCardiac deathSPIRIT IIST ratesDual antiplatelet therapy discontinuationDual antiplatelet therapy interruptionSPIRIT IIIAntiplatelet therapy discontinuationAntiplatelet therapy interruptionLarge pooled analysisRandomised clinical trialsTwo-year ratePatient-level databaseLog-rank testPES cohortTherapy discontinuationTherapy interruptionRandomised trialsStent thrombosisPaclitaxel-eluting stent deploymentPooled analysisClinical trialsDiscontinuationStent deploymentComposite rate